Evidence map›Paper›PMID 28803438›Full record

ArticleJournal of molecular neuroscience : MN2017

Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

Karen L G Farizatto, Sara A McEwan, Vinogran Naidoo, Spyros P Nikas, Vidyanand G Shukla, Michael F Almeida, Aaron Byrd, Heather Romine, David A Karanian, Alexandros Makriyannis and 1 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Karen L G FarizattoBiotechnology Research and Training Center, University of North Carolina-Pembroke, Pembroke, NC, 28372-1510, USA.
Sara A McEwanBiotechnology Research and Training Center, University of North Carolina-Pembroke, Pembroke, NC, 28372-1510, USA.
Vinogran NaidooBiotechnology Research and Training Center, University of North Carolina-Pembroke, Pembroke, NC, 28372-1510, USA.
Spyros P NikasCenter for Drug Discovery, Northeastern University, Boston, MA, USA.
Vidyanand G ShuklaCenter for Drug Discovery, Northeastern University, Boston, MA, USA.
Michael F AlmeidaBiotechnology Research and Training Center, University of North Carolina-Pembroke, Pembroke, NC, 28372-1510, USA.
Aaron ByrdBiotechnology Research and Training Center, University of North Carolina-Pembroke, Pembroke, NC, 28372-1510, USA.
Heather RomineBiotechnology Research and Training Center, University of North Carolina-Pembroke, Pembroke, NC, 28372-1510, USA.
David A KaranianNeurosciences Program, University of Connecticut, Storrs, CT, USA.
Alexandros MakriyannisCenter for Drug Discovery, Northeastern University, Boston, MA, USA.
Ben A BahrBiotechnology Research and Training Center, University of North Carolina-Pembroke, Pembroke, NC, 28372-1510, USA. bahr@uncp.edu.
University of North Carolina at Pembroke · USNortheastern University · USUniversity of Connecticut · USJohnson University · USUniversity of Cape Town · ZA

Funding

Sustainable capacity in Liberia for informing surveillance and response through modeling, biostatistics and computational toolsD71TW010432 · FIC · YALE UNIVERSITY · PI GALVANI, ALISON P · 2016 to 2016
$50k
National Institutes of Health (NIH) DA003801National Institutes of Health (NIH) DA007215National Institutes of Health (NIH) DA009158National Institutes of Health - Research Initiative for Scientific Enhancement (NIH-RISE) grant 5R25GM077634-04U.S. Army Research Office and the Department of Defense Research and Education Program W911nf-15-1-0432
6 · The paper itself

Abstract

The anticholinesterase paraoxon (Pxn) is related to military nerve agents that increase acetylcholine levels, trigger seizures, and cause excitotoxic damage in the brain. In rat hippocampal slice cultures, high-dose Pxn was applied resulting in a presynaptic vulnerability evidenced by a 64% reduction in synapsin IIb (syn IIb) levels, whereas the postsynaptic protein GluR1 was unchanged. Other signs of Pxn-induced cytotoxicity include the oxidative stress-related production of stable 4-hydroxynonenal (4-HNE)-protein adducts. Next, the Pxn toxicity was tested for protective effects by the fatty acid amide hydrolase (FAAH) inhibitor AM5206, a compound linked to enhanced repair signaling through the endocannabinoid pathway. The Pxn-mediated declines in syn IIb and synaptophysin were prevented by AM5206 in the slice cultures. To test if the protective results in the slice model translate to an in vivo model, AM5206 was injected i.p. into rats, followed immediately by subcutaneous Pxn administration. The toxin caused a pathogenic cascade initiated by seizure events, leading to presynaptic marker decline and oxidative changes in the hippocampus and frontal cortex. AM5206 exhibited protective effects including the reduction of seizure severity by 86%, and improving balance and coordination measured 24 h post-insult. As observed in hippocampal slices, the FAAH inhibitor also prevented the Pxn-induced loss of syn IIb in vivo. In addition, the AM5206 compound reduced the 4-HNE modifications of proteins and the β1 integrin activation events both in vitro and in vivo. These results indicate that Pxn exposure produces oxidative and synaptic toxicity that leads to the behavioral deficits manifested by the neurotoxin. In contrast, the presence of FAAH inhibitor AM5206 offsets the pathogenic cascade elicited by the Pxn anticholinesterase.

Indexed as

AmidohydrolasesAnimalsEndocannabinoidsEnzyme InhibitorsFatty Acid Amide HydrolasesFrontal LobeHippocampusInsecticidesMaleNeuroprotective AgentsParaoxonPhenyl EthersRatsRats, Sprague-DawleySeizuresSynaptophysinAM 5206AmidohydrolasesEndocannabinoidsEnzyme InhibitorsFatty Acid Amide HydrolasesInsecticidesNeuroprotective AgentsParaoxonPhenyl EthersSynaptophysinAM5206AnticholinesteraseExcitotoxicityNeuroprotectionParaoxonSynaptic decline

Identifiers

PMID28803438
OpenAlexW2743961957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.